71 results
Page 2 of 4
8-K
EX-99.4
jmfa82o4
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
14t91js9
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
EX-99.1
e5kqkkfaa48e
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.2
782mxt7 bs2
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
EX-99.1
8v4yzumf4nd kj
25 May 23
Other Events
6:08am
8-K
EX-99.1
b9nrq0q mh0mpx6z
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
l4xzm
8 Aug 22
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
4:30pm
8-K
EX-10.1
bhseer3hlbiwyoo1x6
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.2
od29zle
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm
8-K
EX-99.1
2g2jqiunu
7 Jun 22
Other Events
4:06pm
8-K
EX-99.1
8vwtjc6xbm8u4da
7 Apr 22
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
5:27pm
8-K
EX-99.1
ovfnf0m
10 Jan 22
Regulation FD Disclosure
6:40am
8-K
EX-99.1
7pjcxw un7vsw
4 Jan 22
ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF
4:16pm